XXXX and thromboxane in platelets from @entity35 treated with monocrotaline pyrrole.

@entity35 @entity882 @entity2404 @entity6560 @entity16447 @entity3447 @entity120 @entity1426 @entity651 @entity3448 @entity43944 @entity750 @entity1317 @entity4266
@entity6560 pyrrole ( @entity43944 ), a metabolite of the plant toxin @entity6560 , produces @entity1317 , @entity120 , and @entity4266 ( @entity4266 ) in @entity35 by an unknown mechanism. A role for platelets has been suggested by the observation that antibody-induced @entity882 reduces the @entity4266 caused by @entity43944 . The platelet can release a number of vasoconstrictive agents, such as @entity750 ( @entity750 ) and @entity2404 (TxA2), that could possibly contribute to @entity120 . It was of interest to determine whether treatment with @entity43944 alters platelet @entity750 content or alters the release of TxA2 in platelet-rich plasma ( @entity16447 ) in response to aggregation. Fourteen days following treatment with @entity43944 when @entity120 is well-established and @entity4266 is present, the concentration of @entity750 in washed platelets or in platelet-poor plasma was not different in treated and control @entity35 . One day following treatment with @entity43944 , before @entity651 is evident, the concentration of @entity3448 , a stable metabolite of @entity3447 , was higher in unstimulated @entity16447 from treated @entity35 than in control @entity35 . The concentration of @entity3448 was also examined in @entity16447 at 4 days (when @entity651 first appears), 7 days (when pulmonary arterial pressure first increases), and 14 days after treatment with @entity43944 (when @entity4266 is evident). At 4, 7, or 14 days following treatment there was no difference in the concentration of @entity3448 in unstimulated @entity16447 from @entity43944 -treated and control @entity35 . Following stimulation with @entity1426 , the release of @entity3448 at maximal aggregation was not different in @entity16447 from @entity43944 -treated and control @entity35 at any time after treatment. The rate of release of @entity3448 was lower in @entity16447 from @entity35 treated with @entity43944 7 days earlier, but was not different at any other time following treatment. At concentrations up to 250 micrograms/ml, @entity43944 added in vitro to @entity16447 from untreated @entity35 did not affect the concentration of @entity3448 released during aggregation induced by @entity1426 . Only at very high concentrations (1 mg/ml) did @entity43944 abolish the aggregation response and depress @entity3448 release in @entity16447 . These results indicate that @entity43944 treatment does not affect platelet @entity750 content and does not affect basal @entity3448 production or @entity3448 release by platelets stimulated in vitro.
